TomoWave Laboratories Awarded Major National Institutes of Health Grant to Develop Three Dimensional Imaging System for Breast Cancer

Share Article

TomoWave Laboratories, Inc. announces award of $3 million grant from the National Cancer Institute to develop a Laser Optoacoustic Ultrasonic Imaging System (LOUIS-3D™) for Breast Cancer Care.

TomoWave Laboratories, Inc. today announced the award of a $3 million research grant from the National Cancer Institute to develop a multimode Laser Optoacoustic Ultrasonic Imaging System (LOUIS-3D™) for Breast Cancer Care. TomoWave Laboratories develops imaging, sensing and monitoring systems based on the technological combination of light and sound. “Our novel tomography uses the latest advances in laser and ultrasound technologies to identify and characterize abnormal lesions throughout the entire breast. Tomowave’s novel three dimensional imaging system measures ultrasound pulses to display anatomic structures of breast tissues and simultaneously assess the functional state of tissues by converting optical energy absorbed in blood vessels and tumors into sources of ultrasound,” said Dr. Alexander Oraevsky, Chief Technology Officer and the Principal Investigator of this project. TomoWave’s novel three dimensional imaging system will produce three different types of optoacoustic images and two different types of ultrasonic images to provide radiologist with comprehensive diagnostic information which exceeds any current diagnostic device.
Dr. Benjamin Adler, Executive Vice President and General Counsel, stated, "It is not easy to receive federal funding for research in the present economic environment. Our grant proposal received the perfect score from the peer review panel. We are very excited that the National Cancer Institute has selected our program for funding”. According to Dr. Adler, “there is a pressing need for safe and effective diagnostic and imaging systems to replace mammography that uses ionizing radiation for screening and diagnostic purposes”. The existing alternatives to x-ray mammography, such as MRI and PET, are very expensive and require injection of potentially toxic contrast agents.
This major research award will allow TomoWave Laboratories, Inc to optimize its technological approach within 3 years and test its groundbreaking system in clinical studies at the premier cancer hospital, MD Anderson Cancer Center. TomoWave also collaborates with the Washington University at St. Louis in the development of software used in the system.    

Tomowave Laboratories is the internationally recognized leader in optoacoustic imaging research and development. “This new instrumentation provides a significantly cheaper, safer and more versatile alternative to current noninvasive breast imaging modalities, such as x-ray mammography, PET and MRI” stated Dr. Adler. “We expect these imaging systems to be in great demand in both small imaging centers and large hospitals around the world.

Contact:
Tomowave Laboratories, Inc.
Dr. Alexander Oraevsky                
President and Chief Scientific Officer        
713-270-5393                        
aao(at)tomowave(dot)com                    

Dr. Benjamin A. Adler
Executive Vice President and General Counsel
281-813-6150
baa(at)tomowave(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. Alexander Oraevsky